Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adalimumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Genitourinary 1 Endocrine 1 Dermatologic 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 53 lutetium Lu 177 dotatate 41 Magnetic Resonance Spectroscopy 27 Cisplatin 26 Temozolomide 25 pembrolizumab 24 Nivolumab 21 Octreotide 20 lanreotide 19 gallium Ga 68 dotatate 19 cabozantinib 18 Specimen Handling 17 Capecitabine 17 Etoposide 16 lenvatinib 15 pasireotide 14 dabrafenib 14 Sunitinib 14 Carboplatin 14 trametinib 13 Paclitaxel 13 Bevacizumab 13 surufatinib 11 Ipilimumab 11 Doxorubicin 11 3-Iodobenzylguanidine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Injections 10 Thyrotropin Alfa 9 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡